3rd Nov 2005 09:17
Skyepharma PLC03 November 2005 For immediate Release 3 November 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY ORINDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN ORNEW ZEALAND NEITHER THIS ANNOUNCEMENT NOR ANY ACCOMPANYING ANNOUNCEMENT IS AN OFFER OFSECURITIES FOR SALE IN THE UNITED STATES. SECURITIES MAY NOT BE OFFERED OR SOLDIN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION. THESECURITIES TO BE ISSUED PURSUANT TO THE RIGHTS ISSUE HAVE NOT BEEN AND WILL NOTBE REGISTERED UNDER THE US SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANYSTATE OR OTHER JURISDICTION OF THE UNITED STATES. SKYEPHARMA PLC Successful placement of Rights Issue rump Following the announcement earlier today that SkyePharma PLC (the "Company") hasreceived valid acceptances in respect of 103,915,282 New Ordinary Shares underthe 1 for 5 Rights Issue announced on 28 September 2005, the Company nowannounces that, in accordance with the arrangements set out in Part 2, paragraph5 of the prospectus relating to the Rights Issue (the "Prospectus"), CreditSuisse First Boston (Europe) Limited has procured acquirers for the remaining21,712,075 New Ordinary Shares which were not validly taken up in the RightsIssue, at a price of 37 pence per New Ordinary Share. Following completion ofthe Rights Issue, the Company now has 753,764,146 Ordinary Shares in issue. The net proceeds, after deduction of the Rights Issue Price of 30 pence and theexpenses of procuring subscribers (including any commissions and taxes), will,save for amounts less than £5.00 per holding or in respect of New OrdinaryShares representing fractional entitlements, be paid (without interest) to thoseshareholders whose rights have lapsed in accordance with the terms of the RightsIssue, pro rata to their lapsed provisional allotments. Definitions used in the Prospectus shall have the same meanings when used inthis announcement unless the context otherwise requires. Enquiries: Telephone: SkyePharma 020 7491 1777Michael Ashton (Chief Executive Officer)Donald Nicholson (Finance Director)Peter Laing (Director of Corporate Communications) Credit Suisse First Boston (Europe) Limited 020 7888 8888Paul NichollsAndrew ChristieStephanie Leouzon Buchanan Communications 020 7466 5000Tim AndersonMark CourtRebecca Skye Dietrich THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT IS AN ADVERTISEMENT FOR THE PURPOSESOF THE PROSPECTUS RULES OF THE FINANCIAL SERVICES AUTHORITY. NO OFFER,INVITATION OR INDUCEMENT TO ACQUIRE SHARES OR OTHER SECURITIES IN THE COMPANY ISBEING MADE BY OR IN CONNECTION WITH THIS ANNOUNCEMENT. ANY OFFER, INDUCEMENT ORANNOUNCEMENT TO ACQUIRE SHARES IN THE COMPANY HAS BEEN MADE SOLELY BY MEANS OFTHE PROSPECTUS, WHICH WAS PUBLISHED BY THE COMPANY ON 12 OCTOBER 2005, AND ANYDECISION TO KEEP, BUY OR SELL SHARES IN THE COMPANY SHOULD BE MADE SOLELY ON THEBASIS OF THE INFORMATION CONTAINED IN SUCH DOCUMENT. This announcement has been issued by the Company and is the sole responsibilityof the Company. It has been approved solely for the purposes of section 21(2)(b)of FSMA by Credit Suisse First Boston (Europe) Limited of One Cabot Square,London, E14 4QJ. Credit Suisse First Boston (Europe) Limited, which is regulated in the UnitedKingdom by the Financial Services Authority, is acting exclusively for theCompany and for no-one else in connection with the Rights Issue and will not beresponsible to anyone other than the Company for providing the protectionsafforded to customers of Credit Suisse First Boston (Europe) Limited or forproviding advice in relation to the Rights Issue, the contents of thisannouncement or any other matter referred to herein. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L